A PHP Error was encountered

Severity: 8192

Message: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated

Filename: helpers/my_audit_helper.php

Line Number: 8900

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 8900
Function: str_replace

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3362
Function: formatAIDetailSummary

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

[Successful treatment with venetoclax and azacitidine for extramedullary relapse of acute myeloid leukemia after cord blood transplantation]. | LitMetric

A 33-year-old man was diagnosed with acute myeloid leukemia (AML). He was treated with daunorubicin and cytarabine and achieved complete remission. He underwent consolidation therapy with three cycles of venetoclax and azacitidine (VEN+AZA). He received cord blood transplantation following a reduced-intensity conditioning (RIC) regimen. After 19 months, an extramedullary mass appeared in the paranasal sinuses along with vision loss, and relapsed AML was diagnosed based on a biopsy. Palliative irradiation was performed because the patient did not wish to receive a second transplantation. A painful extramedullary mass was found in the inguinal area, and radiation therapy was performed. Subsequently, extramedullary masses appeared in the submandibular region, but radiation therapy was not feasible because the irradiation field overlapped with that of the previous therapy. The extramedullary masses decreased after two cycles of VEN+AZA therapy. This is a rare report of VEN+AZA therapy for an extramedullary relapse of AML.

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.65.1259DOI Listing

Publication Analysis

Top Keywords

venetoclax azacitidine
8
extramedullary relapse
8
acute myeloid
8
myeloid leukemia
8
cord blood
8
extramedullary mass
8
radiation therapy
8
extramedullary masses
8
therapy extramedullary
8
ven+aza therapy
8

Similar Publications

Combination therapy involving azacitidine for acute myeloid leukemia patients ineligible for intensive chemotherapy.

Leuk Res

December 2024

Department of Hematology, Taixing People's Hospital Affiliated to Yangzhou University, Taixing, China; Institute of Hematology, affiliated hospital of Yangzhou University, Taixing, China. Electronic address:

Acute myeloid leukemia (AML) is a complex hematological malignancy predominantly affecting the elderly, with a median diagnosis age of 68 years. Despite advances in treatment, elderly AML patients face suboptimal survival outcomes, with an estimated 5-year survival rate below 20 %. Epigenetic dysregulation, notably DNA methylation, is a key factor in the progression of myelodysplastic syndromes (MDS) to AML.

View Article and Find Full Text PDF

Background: Acute myeloid leukemia (AML) is a malignancy of the bone marrow with a median age at diagnosis of 70 years. AML is difficult to treat, especially in older patients, among whom outcomes have historically been poor. Over the last two decades, a greater understanding of the molecular mechanisms of the pathology has led to the development of new drugs and multiple updates to treatment guidelines.

View Article and Find Full Text PDF

Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenias, hypercellular bone marrow, and dysplastic hematopoietic progenitors. MDS remains a challenge to treat due to the complex interplay between disease-induced and treatment-related cytopenias. Venetoclax, a selective BCL-2 inhibitor, in combination with azacitidine, a hypomethylating agent, is currently being investigated in patients with previously untreated higher-risk MDS.

View Article and Find Full Text PDF

Patients with higher-risk myelodysplastic syndromes (HR MDS) have a median survival of ~1.5 years with azacitidine, and hematopoietic stem cell transplantation is their only curative option. Therefore, improved therapies are needed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!